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Abstract: The gene CDC73 (previously known as HRPT2) encodes
the protein parafibromin. Biallelic mutation of CDC73 is strongly
associated with malignancy in parathyroid tumors. Heterozygous
germline mutations cause hyperparathyroidism jaw tumor syndrome,
which is associated with a high life-time risk of parathyroid carci-
noma. Therefore loss of parafibromin expression by immuno-
histochemistry may triage genetic testing for hyperparathyroidism
jaw tumor syndrome and be associated with malignant behavior in
atypical parathyroid tumors. We share our experience that parafi-
bromin-negative parathyroid tumors show distinctive morphology.
We searched our institutional database for parathyroid tumors dem-
onstrating complete loss of nuclear expression of parafibromin
with internal positive controls. Forty-three parafibromin-negative
tumors from 40 (5.1%) of 789 patients undergoing immuno-
histochemistry were identified. Thirty-three (77%) were external
consultation cases; the estimated incidence in unselected tumors was
0.19%. Sixteen (37.2%) fulfilled World Health Organization 2017 cri-
teria for parathyroid carcinoma and 63% had serum calcium greater
than 3mmol/L. One of 27 (3.7%) noninvasive but parafibromin-
negative tumors subsequently metastasized. Parafibromin-negative
patients were younger (mean, 36 vs. 63 y; P<0.001) and had larger
tumors (mean, 3.04 vs. 0.62 g; P<0.001). Not all patients had full
testing, but 26 patients had pathogenic CDC73 mutation/deletions
confirmed in tumor (n=23) and/or germline (n=16). Parafibromin-
negative tumors demonstrated distinctive morphology including ex-
tensive sheet-like rather than acinar growth, eosinophilic cytoplasm,
nuclear enlargement with distinctive coarse chromatin, perinuclear
cytoplasmic clearing, a prominent arborizing vasculature, and, fre-
quently, a thick capsule. Microcystic change was found in 21 (48.8%).
In conclusion, there are previously unrecognized morphologic clues to
parafibromin loss/CDC73 mutation in parathyroid tumors which,
given the association with malignancy and syndromic disease, are
important to recognize.
Key Words: parathyroid, parathyroid carcinoma, CDC73, par-
afibromin, hyperparathyroidism jaw tumor syndrome
(Am J Surg Pathol 2019;43:35–46)
C DC73 (previously known asHRPT2) is a 17 exon, 133kb gene that maps to 1q31.2 and encodes the protein
parafibromin.1–3 CDC73 functions as a genuine tumor
suppressor gene that is involved in the regulation of p53 and
also as a component of the human PAF1 complex, which
controls RNA polymerase II–mediated transcription.4–6
Pathogenic germline mutations in CDC73 are recognized as
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the cause of the autosomal-dominant hyperparathyroidism
jaw tumor (HPT-JT) syndrome7,8—a rare hereditary tumor
syndrome characterized by parathyroid neoplasms and un-
usual bony lesions of the mandible and maxilla, usually
classified as ossifying fibromas.6,8,9
In HPT-JT syndrome, hyperparathyroidism commonly
occurs at a young age with median first onset between the
third and fourth decade (range, 7 to 65 y).6,9 In addition to its
association with early onset hyperparathyroidism, HPT-JT
syndrome is particularly important to recognize because of its
strong association with parathyroid carcinoma. Parathyroid
carcinoma, rare in all other circumstances, has been reported
to account for 15% to 37.5% of hyperparathyroidism in HPT-
JT patients, and the life-time risk of parathyroid carcinoma in
patients with HPT-JT syndrome has been estimated to be as
high as 15%.6,8–10 For these reasons, it has been recommended
that patients with confirmed or suspected HPT-JT syndrome
should be on surveillance programs beginning at age 5 to
10 years.10 Furthermore, the possibility of HPT-JT syndrome
should be considered in all young patients with HPT.8–10
Biallelic CDC73 mutation/inactivation is also strongly
associated with parathyroid carcinoma occurring outside the
setting of HPT-JT syndrome.2,11 When the diagnosis is re-
stricted to carcinomas, which not only fulfill histologic criteria
for malignancy but also demonstrate biological evidence of
malignant behavior (ie, recurrence or metastasis), the combined
results of several studies indicate that the CDC73 mutation
occurs in up to 77% of parathyroid carcinomas but in <1% of
unselected apparently benign parathyroid adenomas.2,11–15
Furthermore, up to 20% of patients with apparently sporadic
parathyroid carcinoma will be shown to have germline muta-
tions in CDC73 and therefore have previously unrecognized
HPT-JT syndrome.1,13,14 It has therefore been recommended
that all patients with parathyroid carcinoma should be offered
genetic testing for HPT-JT syndrome.8–10,16
Loss of immunohistochemical expression of parafi-
bromin has been used as a marker of biallelic CDC73
mutation inactivation in parathyroid tumors.1,10,12,17–24
However, parafibromin immunohistochemistry (IHC) is
not without controversies and difficulties. Different scor-
ing systems for interpretation are in use and several groups
have reported that parafibromin IHC can be a technically
demanding or difficult antibody to deploy in the routine
clinical setting—summarized in Gill.2 A fair reading of the
literature indicates that, although some groups have found
parafibromin IHC to be useful both in the differential
diagnosis of atypical parathyroid tumors and as a maker
of underlying CDC73 mutation,1,18–24 others found par-
afibromin IHC technically difficult to perform and
interpret.25–27 Furthermore, parafibromin IHC is not
widely available.
Given these difficulties with IHC, it would be par-
ticularly beneficial if morphologic clues to the presence of
CDC73 mutation could be identified. As early adopters
and proponents of parafibromin IHC,1,2,21 we now present
our prospective experience of parafibromin IHC in the
routine clinical setting. We seek to share our finding that
parafibromin-deficient (HPT-JT type, CDC73 mutated)
parathyroid tumors demonstrate distinctive but previously
unrecognized morphologic features that can be used to
triage IHC or, if parafibromin is locally unavailable or
considered unreliable, molecular testing. Further we seek
to address current controversies and uncertainties, in-
cluding criteria for interpretation of parafibromin IHC,
clinical associations of parafibromin-deficient tumors, and
whether noninvasive but parafibromin-deficient/CDC73-
mutated parathyroid tumors (which would be considered
benign under the World Health Organization [WHO] 2017
classification) have metastatic potential.
METHODS
We searched the computerized database of the De-
partment of Anatomical Pathology, Royal North Shore
Hospital, Sydney, Australia, for all parathyroid tumors that
had undergone parafibromin IHC from its introduction into
routine clinical practice in 20061 to 30 June 2017. Although
there were no firm departmental policies and the decision to
perform parafibromin IHC was left up to the discretion of
the reporting pathologists, during this period there were a
variety of relative indications for parafibromin IHC. These
included suspected or confirmed parathyroid carcinoma,
atypical parathyroid adenomas, multiple parathyroid ad-
enomas, recurrent parathyroid tumors, hyperparathyroidism
at a young age, a family history not explained by other
syndromes, extreme hypercalcemia, large size, or the operative
impression of the tumor being adherent to adjacent tissue.
Throughout this period we used the same mouse
monoclonal anti-parafibromin antibody—clone 2H1 (cat.
no.: SC-33638, Santa Cruz, CA).1,17 To achieve positive
staining in internal control tissue, various dilutions, de-
tection systems, and antigen retrieval protocols were re-
quired. The precise conditions varied during the 12-year
period of the study, and, often, several attempts at dif-
ferent titers were required to achieve an interpretable re-
sult for individual cases. As an indication, our current
default approach is to use the primary antibody at a di-
lution of 1 in 400, with heat-induced antigen retrieval in an
alkaline solution for 40 minutes at 97°C, and, thereafter,
adjust the titers if the slides are not interpretable. All cases
initially reported as negative at the time of primary re-
porting were reviewed for this study to confirm this in-
terpretation, or underwent repeat IHC.
Negative (abnormal) staining for parafibromin was
defined as complete loss of nuclear expression in all neo-
plastic cells with internal positive controls in non-neo-
plastic tissue throughout the section (illustrated in Fig. 1).1
Cases with focal loss of staining in only some neoplastic
cells were considered positive. If cases were negative but
there was no staining in internal positive controls, the
staining was considered noninformative and was repeated
with different conditions, as described above until an
interpretable result was achieved. Cytoplasmic staining
was considered nonspecific and disregarded.
All parafibromin-negative cases underwent mor-
phologic review of all available hematoxylin and eosin–
stained sections. Cases were classified as either adenoma
or carcinoma using the criteria outlined in the fourth
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edition of WHO 2017 classification of endocrine neoplasia.28
That is, the diagnosis of parathyroid carcinoma was restricted
to tumors with evidence of unequivocal invasive growth
involving adjacent structures, including the thyroid and soft
tissues, blood vessels, or perineural spaces, or to those tumors
with documented metastases. Specific morphologic features
including invasive growth, vascular space invasion, prominent
nucleoli, a thick capsule, cystic change, mitotic count per 10
hpf (2mm2), sheet-like rather than acinar growth pattern,
eosinophilic cell type, perinuclear cytoplasmic clearing,
a prominent or hemangiopericytomatous vascular pattern,
coagulative necrosis, cytologic atypia, and multinucleation
were also specifically sought and recorded. Long-term clinical
follow-up was sought for all cases by reviewing medical
records and contacting the original referring pathologists
and surgeons. We then developed a control cohort of truly
unselected parathyroid tumors that excluded consultation
cases by searching the anatomic pathology database for all
parathyroid tumors undergoing routine surgical pathology
reporting in our department from the calendar year 2012 to
2015.
Parafibromin-negative parathyroid tumors underwent
Sanger sequencing on archived formalin-fixed paraffin-
embedded (FFPE) neoplastic tissue. This testing was per-
formed blinded to the results of germline mutation testing
undertaken during routine clinical care. Briefly, neoplastic
areas were macrodissected, and genomic DNA was ex-
tracted using the QIAmp DNA FFPE Tissue Kit (Qiagen),
according to the manufacturer’s instructions. Primers were
designed using Primer 3, using the NCBI gene reference,
NG_012691.1 (primer sequences and conditions available
upon request). To identify point mutations, 17 exons of
FIGURE 1. We emphasize that parafibromin can be a difficult stain to perform and interpret and often different conditions are
required to achieve a workable result. This figure shows parafibromin IHC from the same tumor performed on the same block
initially at primary diagnosis (A, B) and repeated 8 years later for this study (C, D). When first performed, all non-neoplastic cells are
completely negative with crisp nuclear staining in internal positive controls (A, B). C, When repeated on archived material, a greater
concentration of primary antibody was required to achieve expression in internal positive controls resulting in nonspecific cyto-
plasmic staining but still completely absent nuclear staining in neoplastic cells. D, The internal controls are weaker in some areas on
repeat staining but still positive. Parafibromin IHC, original magnifications A) 200x, B) and C) 400x, D) 600x.
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CDC73 were amplified by polymerase chain reaction using
MangoTaq polymerase (Bioline). Polymerase chain re-
action products were purified using Wizard SV Gel and
PCR Clean-up system (Promega) according to the manu-
facturer’s instructions. Amplified samples were sequenced
using forward and reverse primers by Sanger sequencing
(service provided by Australian Genome Research Facility,
Sydney, Australia). Mutation nomenclature was according
to accession number NM_024529.4 with numbering start-
ing at the A of the ATG translation initiation codon.
If no mutations were identified by sequencing, samples
underwent multiplex ligation-dependent probe amplification
(MLPA) studies using SALSA P466-A1 Probemix (MRC-
Holland), according to the manufacturer’s instructions. The
relative peak area (RPA)—that is, the individual peak area
in relation to the total of all peak areas in the sample—was
normalized against the RPA of the control samples for each
exon and reference genes included in the probe. A reduction
of 40% to 50% in the ratio of RPA for the exon was con-
sidered to indicate deletion. This study was approved by the
Northern Sydney Local Health District Human Research
Ethics Committee.
RESULTS
During the study period, a total of 815 parathyroid
tumors from 789 patients underwent parafibromin IHC. IHC
was confirmed negative in 43 tumors (5.2%) from 40 patients
(5.1%) with material available for review. The clinical and
demographic details of these patients, including the pre-
operative calcium and parathyroid hormone levels and gland
weights, are presented in Table 1. There was a precisely equal
sex distribution with 20 male patients and 20 female patients.
The median age at diagnosis was 33 years, and the median
weight was 1840mg. The average serum calcium level was
3.12 mmol/L (range 2.49 to 4.0 mmol/L) with 17 of 27 (63%)
patients having a preoperative serum calcium of greater than
3 mmol/L. Thirty-three (77%) of the IHC-negative cases were
from external consultation cases.
In the unselected control cohort excluding con-
sultation cases from 2012 to 2015, there were 1055 patients
of whom 69 (6.5%) underwent parafibromin IHC and only
2 were found to be parafibromin negative (0.19% in-
cidence in a truly unselected cohort). There were several
differences between the unselected cohort and the parafi-
bromin-negative cohort. Eight hundred nineteen (78%) of
the unselected control cohort were female patients versus
50% of the parafibromin-negative cohort (P< 0.001). The
mean age of the unselected control cohort was 63 years
(range, 12 to 95 y) versus 36 years (range, 15 to 74 y) in
the parafibromin-negative cohort (P< 0.001). The mean
weight of the tumors from the unselected control cohort
was 620 mg (range, 58 to 13,800 mg) compared with 3036
mg (range, 231 to 14,000 mg) in the parafibromin-negative
cohort (P< 0.001). In univariate analysis, negative
staining for parafibromin was significantly associated
with younger age of onset, heavier weight, and male sex
(all P< 0.001). In a multivariate model including these
factors, parafibromin negativity remained associated with
age and weight (both P< 0.001), but sex lost significance
(P= 0.187).
The morphologic features of the parafibromin-neg-
ative cases are presented in Table 2 and illustrated in
Figures 2–5. Further whole-slide scanned images from all
tumors are available for review at the Cancer Diagnosis
and Pathology group website www.cancerdxpathology.
org.au. Sixteen (37.2%) parafibromin-negative tumors
fulfilled WHO 2017 criteria for carcinoma (Fig. 2). In
addition to this strong association with malignancy, the
parafibromin-negative tumors demonstrated consistent
TABLE 1. Clinical Details of Parafibromin-negative Parathyroid
Adenoma and Carcinoma












1A 40 M 12.60 2.88 880
1B 380
2 50 M 56.60 3.10 X
3 24 F 3.58 14,000
4 58 F 10.06 2.66 392
5 15 F > 100 3.20 4000
6 39 M 15.02 2.85 1880
7* 42 M X X 1500
8A* 19 M X X 4300
8B* 20 11.2 2.62 377
9* 16 F 27 2.76 684
10 33 F X 4.00 8000
11 59 M 14.49 3.29 1098
12 32 F X 2.53 2040
13 15 M X X 1540
14 18 F 69.30 3.31 1200
15 27 F X 3.20 5350
16 50 M 15.65 3.11 1960
17A 27 M X 2.86 1389
17B X X 485
18 55 M X 2.49 231
19 22 M X 3.30 3347
20 27 M 126 3.18 X
21 60 M 28.35 3.52 3460
22 50 F X X X
23 39 M X X X
24 40 M 13.55 3.01 1229
25† 53 F 23 2.94 700
26† 20 M 7.2 2.7 X
27 59 F X 3.60 3680
28 21 F 20.2 3.54 1000
29 38 M X X X
30 50 F X X X
31 32 F 16.49 3.5 X
32 42 M X X 5020
33 18 M X 3.31 4300
34 74 F X X X
35 20 F X X 8500
36 33 M X X 2311
37 29 F X X 1690
38 26 F X X 1800
39 39 F X X 2556
40 19 F X 3.3 4064
*First-degree relatives from one kindred.
†First-degree relatives from second kindred.
Ca2+ indicates calcium; F, female; M, male; PTH, parathyroid hormone; X,
data unknown.
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and distinctive morphology. The neoplastic cells displayed
eosinophilic cytoplasm, which frequently lacked the
granularity of usual parathyroid oxyphil cells. Another
particularly distinctive feature was the very frequent
presence of perinuclear cytoplasmic clearing imparting
an almost koilocytic quality, which in some areas
was reminiscent of chromophobe renal carcinoma. In most
instances, there was quite prominent nuclear enlargement but,
sometimes, with relatively preserved nuclear-to-cytoplasmic
(N/C) ratios, giving a peculiar ancient quality to the atypia.
In several cases, there were subclonal nodules, which
demonstrated greater nuclear atypia, again sometimes with
a relatively preserved N/C ratio.
The chromatin was usually speckled, often, coarsely
so, sometimes with prominent nucleoli. Rather than being
arranged in an acinar architecture, the neoplastic cells
usually grew in solid sheets. Microcystic change was not
uncommon, being found in 21 (48.8%) cases; however,
grossly evident macrocystic change was absent. In most
cases, there was a conspicuous arborizing vasculature, at
least focally. In a few cases, there were some prominent
dilated vessels imparting a hemangiopericytomatous
quality, which contributed to the microcystic appearance
appreciated at low power. Some cases were associated
with a thick capsule. Multinucleation was noted in 5 (12%)
cases. Broad bands of fibrosis were rare.
The results of molecular testing are presented in
Table 3. Of the 39 tumors from 38 patients that underwent
molecular testing on FFPE tumor tissue, pathogenic
CDC73 variants were confirmed in 23. Eight (34.8%) of
these were large-scale deletions. Loss of heterozygosity
was confirmed in 4 tumors, and, in an additional 2 tumors,
(#6 and #23) putative “second-hit” somatic variants were
identified that were absent in germline testing.
Of the 40 patients, 24 had some degree of germline
mutation testing as part of their clinical care. In 16 (66.7%),
pathogenic germline variants were identified, of which 2 were
whole-gene deletions. Of note, 4 of the patients in whom no
germline mutations were identified did not undergo MLPA,
and 3 of these patients had large-scale deletions in their




























1A Adenoma Absent Absent Absent 1+ Absent 1 3+ 3+ 2+ 3+ Absent
1B Adenoma Absent Absent Absent 1+ Absent 0 3+ 3+ 2+ 2+ Absent
2 Carcinoma Present Absent Absent 3+ Absent 1 3+ 2+ 3+ 1+ Absent
3 Carcinoma Present Absent Absent 3+ 1+ 1 3+ 3+ 2+ 2+ Absent
4 Carcinoma Present Absent Present 3+ Absent 1 3+ 3+ 3+ Absent Absent
5 Adenoma Absent Absent Absent Absent Absent 1 3+ 3+ 1+ Absent Absent
6 Adenoma Absent Absent Absent Absent 1 0 3+ 3+ 2+ Absent Absent
7* Adenoma Absent Absent Absent 2+ Absent 0 3+ 3+ Absent 1+ Absent
8A* Adenoma Absent Absent Absent 3+ 3+ 0 3+ 3+ 1+ Absent Absent
8B* Adenoma Absent Absent Present 3+ 3+ 2 3+ 3+ 3+ Absent Absent
9* Adenoma Absent Absent Absent 1+ 1+ 0 3+ 3+ 2+ 1+ Absent
10 Carcinoma Present Absent Absent 3+ 1+ 1 3+ 3+ 3+ Absent Absent
11 Carcinoma Present Absent Absent 1+ 3+ 2 3+ 3+ 2+ 1+ Absent
12 Adenoma Absent Absent Absent 2+ 2+ 0 3+ 3+ 2+ 1+ Absent
13 Adenoma Absent Absent Present 2+ 1+ 1 3+ 3+ 3+ 2+ Absent
14 Adenoma Absent Absent Absent 3+ Absent 1 3+ 3+ 1+ Absent Absent
15 Adenoma Absent Absent Absent 2+ Absent 1 3+ 3+ 3+ 2+ Absent
16 Adenoma Absent Absent Absent 3+ 2+ 0 3+ 3+ 3+ Absent Absent
17A Adenoma Absent Absent Absent 2+ Absent 0 3+ 3+ 2+ 1+ Absent
17B Adenoma Absent Absent Absent 2+ Absent 0 3+ 3+ 2+ 1+ Absent
18 Adenoma Absent Absent Absent 1+ Absent 0 3+ 3+ 2+ 1+ Absent
19 Carcinoma Present Absent Absent 2+ 2+ 0 3 3+ 1+ 1+ Absent
20 Carcinoma Present Absent Absent 3+ Absent 2 3+ 3+ 2+ Absent Present
21 Adenoma Absent Absent Present 2+ Absent 1 3+ 3+ 2+ 3+ Absent
22 Carcinoma Present Absent Absent 2+ Absent 1 3+ 2+ 1+ 1+ Absent
23 Adenoma Absent Absent Present 3+ Absent 0 3+ 3+ 3+ 1+ Absent
24 Adenoma Absent Absent Absent 2+ 2+ 0 3+ 3+ 3+ 2+ Absent
25† Carcinoma Present Absent Absent 2+ Absent 2 3 3+ 2+ Absent Absent
26† Adenoma Absent Absent Present Absent 1+ 0 2+ 3+ 2+ 2+ Absent
27 Carcinoma Present Present Present 2+ Absent 1 3+ 3+ 3+ Absent Absent
28 Carcinoma Present Present Absent 2+ Absent 1 3+ 3+ 2+ 2+ Absent
29 Carcinoma Present Absent Present 1+ Absent 1 3+ 3+ 1+ 1+ Present
30 Carcinoma Present Absent Present 3+ 1 1 3+ 3+ 3+ 1 Absent
31 Carcinoma Present Absent Absent 2+ Absent 1 3+ 3+ 3+ 1 Absent
32 Adenoma Absent Absent Present 1+ 2 0 3+ 3+ 1+ 1 Absent
33 Adenoma Absent Absent Absent 3+ 3 0 3+ 3+ 2+ 1 Absent
34 Adenoma Absent Absent Absent 2+ Absent 0 3+ 3+ 2+ Absent Absent
35 Adenoma Absent Absent Absent 3+ 2+ 1 1+ 3+ 1+ 2+ Absent
36 Carcinoma Present Absent Present 3+ Absent 2 3+ 3+ 2+ 1+ Present
37 Adenoma Absent Absent Absent 3+ Absent 1 3+ 3+ 2+ 1+ Absent
38 Adenoma Absent Absent Absent 3+ Absent 1 3+ 3+ 2+ 1+ Absent
39 Carcinoma Present Absent Present 2+ 2+ 0 3+ 2+ 3+ 1+ Absent
40 Adenoma Absent Absent Absent 1+ 3+ 0 3+ 3+ 2+ 3+ Absent
*First-degree relatives from one kindred.
†First-degree relatives from second kindred.
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tumors. Therefore, germline deletions could not be excluded.
In 3 tumors, somatic testing was not able to identify the known
germline CDC73 variants because of incomplete coverage.
There were no tumors in which we could confidently
exclude CDC73 mutation. One case (#4) had neither so-
matic nor germline testing performed, and, in 13 cases,
somatic sequencing data had insufficient coverage in at
least some exons. Therefore, a total of 26 of 40 (65%)
patients with parafibromin-negative tumors had confirmed
pathogenic somatic and/or germline CDC73 mutations,
FIGURE 2. In accordance with the WHO 2017 classification
the diagnosis of parathyroid carcinoma was restricted to cases
that demonstrated unequivocal invasive growth. Hematoxylin
and eosin, whole mount.
FIGURE 3. Parafibromin-deficient (HPT-JT type, CDC73mutated)
parathyroid tumors are characterized by cells with eosinophilic
cytoplasm demonstrating a sheet-like growth pattern. At this
magnification both the prominent arborizing vasculature and the
distinctive perinuclear cytoplasmic clearing are also evident.
Hematoxylin and eosin, original magnification 100x.
FIGURE 5. In some cases, both multinucleation and nuclear atypia
were present. The nuclear atypia was sometimes associated with
smudged chromatin and relatively preserved N/C ratios imparting
an ancient quality. An atypical mitotic figure is noted in the upper
right quadrant. Hematoxylin and eosin, original magnification 400x.
FIGURE 4. Parafibromin-deficient (HPT-JT type, CDC73 mu-
tated) parathyroid tumors demonstrate eosinophilic cytoplasm,
but these tumor cells usually lack the distinct cytoplasmic
granularity of usual oxyphil cells and are notable for their relative
nuclear enlargement and perinculear cytoplasmic clearing.
Hematoxylin and eosin, original magnification 200x.
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1A Adenoma Incomplete coverage in exons 7, 13, 14




114 AWOD 2 primary tumors removed at
first operation
1B Adenoma Not tested
2 Carcinoma Exon 17 Del heterozygous Not tested 95 AWOD Follow-up wide local excision,
no residual disease
3 Carcinoma Not tested c.685_688delAGAG;
p.(Arg229Tyr)fs*27
73 AWD 58mo to first recurrence
4 Carcinoma Not tested No mutation
identified. MLPA not
performed
5 AWOD Past history of parathyroid





Exon 17 Del Heterozygous No mutation
identified. MLPA not
performed
72 AWD 8mo to first recurrence. 28mo to
second recurrence. Disease free
at 8 y. History presented in
detail in text





7‡ Adenoma c.157 G>T, p.(Glu53*) and LOH c.157 G>T, p.
(Glu53*)
120 AWOD 4 operations all for
metachronous primary
tumors
8A‡ Adenoma c.157 G>T, p.(Glu53*) and LOH c.157 G>T, p.
(Glu53*)
46 AWOD Second tumor was
metachronous primary,
resected 9 mo later
8B‡ Adenoma c.157 G>T, p.(Glu53*) and LOH
9‡ Adenoma c.157 G>T, p.(Glu53*) and LOH c.157 G>T, p.
(Glu53*)
43 AWOD
10 Carcinoma Exon 2-10 Del heterozygous No mutation
identified. MLPA not
performed
67 AWD Recurrence at 60 mo
11 Carcinoma IVS7+2T>G Heterozygous IVS7+2T>G 33 AWOD
12 Adenoma Incomplete coverage in exons 7, 13 for
sequencing. No evidence of deletion/
duplication on MLPA
Not tested 34 AWOD
13 Adenoma c.415 C>T, p.(Arg139*) Heterozygous c.415 C>T, p.
(Arg139*)
31 AWOD
14 Adenoma Incomplete coverage in sequencing. No
evidence of deletion/duplication on
MLPA
Not tested 27 AWOD
15 Adenoma Incomplete coverage in exons 7, 13, 16
for sequencing. No evidence of
deletion/duplication on MLPA
Not tested 25 AWOD
16 Adenoma c.226 C>T,p.(Arg76*) Heterozygous c.226 C>T,p.
(Arg76*)
59 AWOD




18 Adenoma c.226 C>T,p.(Arg76*) Heterozygous c.226 C>T,p.
(Arg76*)
24 AWOD
19 Carcinoma Incomplete coverage in exons 7, 13, 14,
16 for sequencing. No evidence of
deletion/duplication on MLPA
Not tested 19 AWOD
20 Carcinoma c.415 C>T, p.(Arg139*) Heterozygous Not tested 18 AWOD
21 Adenoma Exon 3 Del Heterozygous Not tested 13 AWOD
22 Carcinoma Incomplete coverage in exons 4-8, 13,
14 for sequencing. No evidence of
deletion/duplication on MLPA
Not tested 48 AWD
23 Adenoma IVS2+1 G>C And c.19 C>A; p.
(Asn66Lys) (both heterozygous)
IVS2+1G>C 1 AWOD
24 Adenoma Incomplete coverage in exons 6, 7, 13
for sequencing. No evidence of
deletion/duplication on MLPA
Not tested 7 AWOD
25§ Carcinoma Incomplete coverage in sequencing. No




60 AWOD Intraosseous lesion mandible
confirmed with biopsy
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and, in the remaining 14 patients, there was insufficient
coverage to exclude a pathogenic mutation.
The long-term follow-up of the parafibromin-neg-
ative patients is presented in Table 3—median duration of
follow-up 26 months. One patient (2.5%) developed a jaw
tumour with the typical characteristics of the type of
ossifying fibroma reported in the setting of HPT-JT
syndrome.6 Of the 16 patients who fulfilled WHO 2017
criteria for carcinoma at first presentation, subsequent
recurrence with the properties of malignant disease rather
than metachronous tumors, that is, infiltrative or
destructive growth, vascular invasion, and distant
metastasis, arose in 5 (31%) patients after intervals of up
to 10 years. Several of the patients with histologically
benign parathyroid adenoma developed recurrent disease
that could be definitively attributed to metachronous
tumors arising in a different parathyroid gland.
However, 1 patient, with a noninvasive primary tu-
mor and therefore classified as adenoma under the WHO
2017 system, developed recurrent disease that seemed to
represent unequivocal metastatic carcinoma in the absence
of a second metachronous or synchronous tumor and is
presented in detail. Patient 5 initially presented at the age
of 15 with a serum calcium level of 3.2 mmol/L (normal
range, 2.2 to 2.7 mmol/L) and a serum parathyroid hor-
mone level of > 100 pmol/L (normal range, 1.05 to 6.83
pmol/L). A right inferior parathyroid tumor weighing 4 g
was removed. This tumor was fragmented upon receipt.
The entire specimen was embedded in 7 blocks. It dem-
onstrated typical features for a parafibromin-deficient tu-
mor, including a solid growth pattern, eosinophilic
cytoplasm, and some perinuclear cytoplasmic clearing.
Although the fragmentation of the tumor made assess-













26§ Adenoma Incomplete coverage in sequencing. No





27 Carcinoma Incomplete coverage in sequencing. No
evidence of deletion/duplication on
MLPA
Not tested 3 AWOD
28 Carcinoma Exon 1 Del Heterozygous Not tested 140 AWD
29 Carcinoma c.704del C, p.(Thr235Lys)fs*22.
Heterozygous
Not tested 12 AWOD
30 Carcinoma Incomplete coverage in exon 4-7, 13,
14, 16 for sequencing. No evidence of
deletion/duplication on MLPA
Not tested 12 AWD
31 Carcinoma c.668delA, p.(Asp223Val)fs*34
Heterozygous
Not tested 12 AWOD
32 Adenoma Incomplete coverage in sequencing. No
evidence of deletion/duplication on
MLPA
Not tested 1 AWOD
33 Adenoma Incomplete coverage in exon 6, 7, 13,
16 for sequencing. No evidence of
deletion/duplication on MLPA
Not tested 48 AWOD




35 Adenoma Incomplete coverage in exon 7 for
sequencing. No evidence of deletion/
duplication on MLPA
Not tested 1 AWOD
36 Carcinoma Whole-gene deletion Whole-gene deletion 1 AWOD
37 Adenoma Incomplete coverage in sequencing. No
evidence of deletion/duplication on
MLPA
Not tested 1 AWOD




39 Carcinoma Incomplete coverage in sequencing. No
evidence of deletion/duplication on
MLPA
Not tested 1 AWOD
40 Adenoma Whole-gene deletion Whole-gene deletion 3 AWOD
*Coverage for exons 1 and 3 was poor for all samples. Additional incomplete coverages have been listed.
†Diagnosis revised to carcinoma upon metastasis.
‡ First-degree relatives from one kindred.
§First-degree relatives from second kindred.
AWD indicates alive with disease; AWOD, alive without disease; LOH, loss of heterozygosity.
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(Fig. 6), there was no invasive growth evident. Of note, all
slides from this initial tumor were reviewed by 3
pathologists (2 with subspecialty expertise in endocrine
pathology) and reviewed again for this paper, and all
reviewers agreed that there was no invasive growth and
therefore the tumor was best classified as adenoma. The
hypercalcemia resolved immediately after surgery, and, in
fact, the patient developed hungry bone syndrome.
Eight months later the patient developed recurrent
hyperparathyroidism. She underwent repeat surgical ex-
ploration, and each of the left superior, left inferior, and
right superior parathyroid glands were identified and con-
firmed on biopsy to be histologically normal and to dem-
onstrate retained parafibromin expression. The central neck
compartment and the site of the previously resected right
inferior parathyroid were also cleared and lacked neoplastic
tissue. The hyperparathyroidism did not resolve. Six
months later, imaging revealed enlarged level 3/4 lymph
nodes, and the patient underwent a modified right neck
dissection during which 4 separate deposits of parafi-
bromin-negative parathyroid carcinoma were identified at
level 4—an area that was outside the previous operative
fields. The hyperparathyroidism resolved but then recurred
14 months later when the patient underwent further re-
section of parathyroid carcinoma adherent to the recurrent
laryngeal nerve and cricothyroid muscle in the central neck
compartment. MLPA studies of FFPE tissue from the
original tumor demonstrated deletion of exon 17. No
germline mutation was identified on clinical sequencing of
peripheral blood; however, germline tissue did not undergo
MLPA studies, and therefore large-scale deletions could
not be excluded. At last follow-up, 7 years after first pre-
sentation, she was disease free.
DISCUSSION
In this report we describe the previously unrecognized
but distinctive morphology of parafibromin-deficient
(HPT-JT type, CDC73 mutated/inactivated) parathyroid
neoplasms and propose that they be considered a distinct
subtype of parathyroid tumor. We accept that there were
no firm department guidelines for which cases underwent
parafibromin IHC and that therefore there may be an
ascertainment bias toward a distinct morphology as we
became more familiar with the stereotypical morphology of
these cases. These tumors are characterized by a sheet-like
growth of neoplastic cells. Although this sheet-like pattern is
frequently interrupted by an arborizing vasculature, it con-
trasts with the acinar architecture that is found in the ma-
jority of parathyroid neoplasms. A particular feature of these
tumors is their distinctive eosinophilic cytoplasm. Usually, at
least in some areas, the eosinophilic cytoplasm characteristic
of parafibromin-deficient tumors demonstrates a unique
appearance that is different to and, with experience, may be
FIGURE 6. Patient 5’s case was initially classified as adenoma at first excision (A–C) but subsequently demonstrated unequivocal
metastasis warranting classification as carcinoma (D–F). At initial resection, the tumor came out easily but was fragmented (A)
making assessment of the interface with non-neoplastic tissue difficult. B, However, no unequivocal invasive growth was evident. C,
At high power the primary tumor demonstrated cytologic features of parafibromin deficiency, including nuclear enlargement with
relatively preserved N/C ratios and eosinophilic but not oxyphilic cytoplasm. D, At recurrence, the tumor was resected from the
level 3/4 lymph nodes, effectively excluding seeding of benign disease from the previous operation. The recurrence demonstrated
an unequivocal invasive growth pattern into soft tissue (E), but it still showed similar cytologic features to that seen in the original
tumor (F). Hematoxylin and eosins, original magnifications. B) 100x, C) 400x, E) 100x , F) 200x.
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distinguished from the very granular cytoplasm of the
type of oxyphil cells that commonly occur elsewhere in
parafibromin-deficient tumors, but are not uncommon in
non-neoplastic parathyroid tissue and other parathyroid
adenomas.29 Other features characteristic of parafibromin-
negative parathyroid tumors include nuclear enlargement
(sometimes with preserved N/C ratios and smudged or coarse
chromatin) and distinctive perinuclear cytoplasmic clearing
imparting an almost koilocytic-like appearance. Microcystic
change or a thick hyalinized fibrous capsule are also com-
monly present, but these features are not uncommon in usual
adenomas. To familiarize pathologists with these morphologic
features, whole-slide scanned images from all tumors in this
study are available for review at the Cancer Diagnosis and
Pathology group website www.cancerdxpathology.org.au.
Clinical experience with parafibromin IHC is
mixed.1,18–27 Our prospective experience of parafibromin IHC
over the 12-year period of this study during which we per-
formed IHC on 815 tumors is that, while it can be a techni-
cally difficult stain to perform and interpret, meaningful
results can be achieved with care and time. The very high
specificity of negative parafibromin IHC is supported by the
confirmation of pathogenic germline or somatic mutations in
26 of 40 (65%) patients, with a high likelihood that there are
further mutations that have been missed because of in-
complete coverage, and the limited sensitivity of sequencing
and MLPA on FFPE tissue. Evidence for the suboptimal
sensitivity of sequencing using FFPE tissue includes the fact
that we did not identify the known germline mutation in the
somatic testing of 3 patients with confirmed HPT-JT syn-
drome despite the fact that we did not microdissect the tissue.
However, we fully accept the limitations of parafi-
bromin IHC, and our experience is that a diagnostic result
cannot always be obtained. In a significant number of
cases, we had to repeat the stain with different concen-
trations and antigen retrieval conditions to achieve an
interpretable result—that is, positive staining in non-
neoplastic internal controls as well as negative staining in
neoplastic cells. We commonly find that, in larger tumors,
which were otherwise positive for parafibromin, toward
the center of specimens, there is focal nonspecific loss of
nuclear expression in neoplastic cells associated with de-
creased or absent expression in internal positive controls—
a pattern of staining we still interpret as positive. All the
cases were prospectively identified as parafibromin neg-
ative (and confirmed on repeat testing); therefore age
in paraffin blocks does not appear to be a significant
confounding factor, particularly if attention is payed to
the need for internal positive controls.
We note that different criteria have been used for
parafibromin interpretation by different groups. We1,21
and others18,20,24 require completely absent nuclear ex-
pression of parafibromin in all neoplastic cells in the
presence of an internal positive control in non-neoplastic
tissue—an approach highly analogous to that commonly
used for DNA mismatch repair IHC interpretation in
colorectal carcinoma.30 In contrast, some other groups
consider focal loss of parafibromin expression as sufficient
to indicate negative staining.19,22,23 This study confirms
the high specificity of our approach to interpretation but
was not intended or designed to assess sensitivity. Indeed,
we have previously reported that, although truncation or
large-scale deletions of CDC73 are consistently associated
with completely negative parafibromin expression, some
pathogenic point mutations may be associated with re-
tained positive expression for parafibromin using our
criteria.1,21 The reported incidence of large-scale germline
deletions of CDC73 is up to 35%,31 similar to our finding
of 8 of 23 (34.8%) in the somatic testing in our series. We
emphasize that large-scale deletions are usually not de-
tected by sequencing alone, and several of the patients
thought to lack germline CDC73 mutations in this and
previous studies did not have MLPA studies performed,
and therefore may have had unrecognized deletions.
There is an extensive literature linking CDC73 mu-
tations with parathyroid carcinoma.2,11–15,32 However, the
role of CDC73 mutation as a marker of malignancy in
atypical parathyroid tumors remains controversial. This
may be because mutation testing is not readily available,
and some groups have found parafibromin IHC
unreliable.2,25–27,33 However, we also believe it is partially
because the accuracy of parafibromin IHC is commonly
compared with morphologic criteria as a gold standard,
despite evidence that morphology is an imperfect predictor
of biologically malignant behavior. It can be argued that
parathyroid carcinoma is both “overdiagnosed” and
“underdiagnosed.” That is, the majority of cases diag-
nosed as carcinoma on the basis of histologic criteria alone
do not recur, and the diagnosis of carcinoma is frequently
not made by histologic criteria until metastasis/recurrence
has occurred.2,34–37 It is therefore worth noting that 16 of
the 40 (40%) patients with tumors that fulfilled WHO
criteria for malignancy demonstrated complete loss of
parafibromin staining in their tumors and, most im-
portantly, in 5 (31%) of these patients, the tumor went on
to demonstrate unequivocal malignant behavior. In con-
trast, although parafibromin IHC was not performed in all
tumors, loss of expression was found in only 2 of 1055
(< 0.2%) of truly unselected parathyroid tumors.
When confronted with an atypical parathyroid tu-
mor that does not fulfill WHO 2017 criteria for malig-
nancy, we have taken the pragmatic approach that tumors
lacking immunohistochemical evidence of CDC73 muta-
tion/inactivation are very unlikely to recur and can be
safely followed-up similarly to benign adenomas.33 Of
course, this is useful in the great majority of cases pri-
marily because CDC73 mutation and recurrence after re-
section of an atypical adenoma are both rare events.
However, it leaves the very real difficulty of how to clas-
sify parafibromin-negative parathyroid tumors that do not
fulfill WHO criteria for malignancy. We now believe that
these are best classified simply as “parafibromin-deficient
(HPT-JT type, CDC73 mutated) parathyroid tumors” and
considered a distinct entity.
There are isolated case reports of CDC73mutated but
noninvasive and therefore “histologically benign” para-
thyroid tumors that have subsequently metastasized.38
Some of these events may be attributable to metastasis from
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other unrecognized synchronous or metachronous primary
tumors.6 Our experience with patient 5 in this report, where
every possible effort was made to exclude a second primary
tumor, adds another case of a noninvasive parathyroid tumor
associated with CDC73 mutation which subsequently
behaved in a malignant manner. This supports our approach
that parafibromin-deficient parathyroid tumors have some
metastatic potential.2 However, it is clear that the metastatic
potential is very low in the absence of invasive growth. When
care was taken to exclude second primary tumors, none of
the 26 other parafibromin deficient tumors that did not
fulfill WHO criteria for carcinoma behaved aggressively at
long-term follow-up. Therefore, although we believe that
recurrence and metastasis may occur in parafibromin-deficient
tumors lacking WHO 2017 criteria for malignancy, we
emphasize that this is an unusual event. Indeed, the risk of
metastasis in noninvasive parafibromin-deficient tumors is
probably even lower than the 3.7% estimated in our study,
given that it was subject to a selection bias toward identifying
such patients (as recurrence/metastasis would be considered
an indication for parafibromin IHC).
In our experience, much more common than metastasis
from a noninvasive parafibromin-deficient tumor are cases
where malignant features were only recognized on pathologic
review of parafibromin-deficient tumors that subsequently
behaved in a malignant manner.39 Because of the very low
risk of metastasis from noninvasive tumors we do not rec-
ommend altering the WHO criteria for parathyroid carcino-
ma to include all parafibromin-deficient tumors. However, we
would recommend that particular care should be taken in
examining all parafibromin-deficient tumors, perhaps with a
lower threshold for diagnosing invasive growth, and therefore
parathyroid carcinoma, in equivocal cases.
Patients with confirmed HPT-JT syndrome have a
very high risk of recurrence in the same or other glands,
which is at least 25%, but which may occur in the majority
of patients at follow-up extending to 30 years.6,8,9,38,40–43
Therefore, the diagnosis of parafibromin-deficient (HPT-JT
type) parathyroid tumors should precipitate long-term fol-
low-up for the possibility of late recurrence or metachronous
disease, whether or not WHO criteria for malignancy are
met. That is, simply identifying these unique tumors not as
benign or atypical adenomas but as parafibromin-deficient
(HPT-JT type, CDC73 mutated) parathyroid tumors should
be sufficient to justify long-term follow-up and adequately
convey the risk of recurrence, which is usually attributable to
metachronous disease in patients with germline mutations
and only very rarely to true metastasis from non-invasive
tumors. Confirmation of germline CDC73 mutation in such
patients also allows for cascade testing of family members, to
identify carriers for whom screening for parathyroid disease
is then appropriate.1,10,12,17–24,44–48
In conclusion, we report that parafibromin-deficient
(HPT-JT type, CDC73 mutated) parathyroid tumors
demonstrate distinctive morphologic features including
sheet-like rather than acinar architecture, eosinophilic (but
not very oxyphilic) cytoplasm, nuclear enlargement with
distinctive chromatin and perinuclear cytoplasmic clear-
ing, a prominent arborizing vasculature sometimes with a
hemangiopericytomatous quality, and, frequently, a thick
capsule. Other important clues to the diagnosis include a
younger age of onset (mean, 36 vs. 63 y; P<0.001), a larger
size (mean, 3.04 vs. 0.62 g; P<0.001) and more marked
hypercalcemia (average 3.12 mmol/L in our series). Although
parafibromin IHC can be technically difficult to perform and
interpret, recognition of these tumors is important because of
their strong association with malignancy (rare in all other
circumstances) and HPT-JT syndrome. If a parafibromin-
deficient (HPT-JT type) parathyroid tumor is identified, we
recommend particularly careful assessment for malignancy
by conventional morphologic criteria and genetic testing by
both sequencing and MLPA for germline CDC73 mutation/
deletion—present in at least 40% of patients in our series but
probably more. For noninvasive parafibromin-deficient
(HPT-JT type, CDC73 mutated) tumors, we still recommend
long-term follow-up, primarily because of the risk of meta-
chronous disease but also because of the risk of aggressive
behavior in a small minority of cases.
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